Jason Todd Yustein

This study evaluates the efficacy of cabozantinib plus TIGIT blockade in osteosarcoma models, finding improved outcomes in p53-driven tumors but resistance in MYC-hyperactivated models due to myeloid recruitment and ECM remodeling.

SPARC improves trajectory inference by jointly modeling state progression and transitions between conditions, revealing osteoclastogenesis-associated malignant states in osteosarcoma metastasis.

This paper demonstrates the use of 19F-Eu-based contrast agents for real-time hypoxia imaging in tumors, showing reliable delivery and integration with spatial biology for biomarker identification.

This study shows that deleting Regnase-1 in CAR T cells enhances their antitumor activity against osteosarcoma by creating a proinflammatory tumor microenvironment.